Arrowhead Pharmaceuticals (ARWR) Net Margin (2010 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Net Margin came in at 186.57% in Q1 2026, down 25435.0% YoY from N/an in Q1 2025, and down 1844.24% on a QoQ basis from 10.7% in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) Net Margin (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 17 years of Net Margin data on file, last reported at 186.57% in Q1 2026.
- Quarterly Net Margin fell 25435.0% year-over-year to 186.57% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 43.71% (down 1535.0% YoY) and the FY2025 annual result came in at 3.63%, up 1717324.0% from the prior year.
- Net Margin declined to 186.57% in Q1 2026, from 10.7% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 67.78% in Q1 2025 to a low of 7008.72% in Q4 2024.
- A 5-year average of 958.11% and a median of 204.43% in 2026 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2023 — Net Margin plunged 374551 bps — and 2025, when it surged 701942 bps.
- Tracing ARWR's Net Margin over 5 years: stood at 66.82% in 2022, then plunged by 5605 bps to 3812.33% in 2023, then sank by 84 bps to 7008.72% in 2024, then soared by 100 bps to 10.7% in 2025, then plunged by 1844 bps to 186.57% in 2026.
- The last three Net Margin figures came in at 186.57% (Q1 2026), 10.7% (Q4 2025), and 6.29% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - | -237.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -237.75% |
| Mar 31, 2026 | -186.57% |
| Dec 31, 2025 | 10.70% |
| Sep 30, 2025 | 6.29% |
| Jun 30, 2025 | -643.53% |
| Mar 31, 2025 | 67.78% |
| Dec 31, 2024 | -7,008.72% |
| Dec 31, 2023 | -3,812.33% |
| Sep 30, 2023 | -689.66% |
| Jun 30, 2023 | -657.98% |
| Mar 31, 2023 | 32.60% |
| Dec 31, 2022 | -66.82% |
| Sep 30, 2022 | -272.18% |
| Jun 30, 2022 | -222.28% |
| Mar 31, 2022 | 29.23% |
| Dec 31, 2021 | -229.13% |
| Sep 30, 2021 | -165.54% |
| Jun 30, 2021 | -65.21% |
| Mar 31, 2021 | -81.73% |
| Dec 31, 2020 | -97.32% |